Denali Therapeutics Inc. (DNLI) vs Parabilis Medicines, Inc. (PBLS)
A side-by-side comparison of Denali Therapeutics Inc. and Parabilis Medicines, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DNLI
Denali Therapeutics Inc.
$19.77HealthcareDelayed quote: Oct 6, 2026, 11:55 AM EDT
PBLS
Parabilis Medicines, Inc.
$28.97HealthcareDelayed quote: Oct 6, 2026, 11:50 AM EDT
Total return — DNLI vs PBLS
growth of $100 · dividends reinvested · last 1yDNLI +1.9% (+1.9%/yr)PBLS +47.7% (+47.7%/yr)PBLS compounded faster over this window
DNLI PBLS
DNLI vs PBLS: by the numbers
- •PBLS is the larger company ($3.38B vs $3.14B market cap).
- •Both run net losses; PBLS's is the smaller (0.00% vs -14191.20% net margin).
Metrics side by side
Valuation
| Metric | DNLI | PBLS |
|---|---|---|
| P/S ratio | 870.59 | N/A |
| P/B ratio | 3.76 | 3.22 |
Profitability
| Metric | DNLI | PBLS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | -14191.20% | 0.00% |
| ROE | -61.24% | N/A |
| ROIC | -50.82% | -409.85% |
Growth (annualized)
| Metric | DNLI | PBLS |
|---|---|---|
| Revenue CAGR (5Y) | 20.68% | N/A |
| Total return CAGR (5Y) | -16.91% | N/A |
Go deeper
Dig into the metrics
Denali Therapeutics ROEParabilis Medicines ROEDenali Therapeutics operating marginParabilis Medicines operating marginDenali Therapeutics revenue growthParabilis Medicines revenue growthDenali Therapeutics free cash flowParabilis Medicines free cash flow
Denali Therapeutics & Parabilis Medicines appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.